• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Nuvalent Inc.

    2/27/25 7:02:03 AM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NUVL alert in real time by email
    S-8 1 d904176ds8.htm S-8 S-8

    As filed with the Securities and Exchange Commission on February 27, 2025

    Registration No. 333-   

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    Under

    The Securities Act of 1933

     

     

    NUVALENT, INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   81-5112298

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

    One Broadway, 14th Floor

    Cambridge, MA 02142

    (Address, including zip code, of Registrant’s principal executive offices)

    Nuvalent, Inc. 2021 Stock Option and Incentive Plan

    Nuvalent, Inc. Amended and Restated 2021 Employee Stock Purchase Plan

    (Full title of the plan)

    James R. Porter

    Chief Executive Officer

    One Broadway, 14th Floor

    Cambridge, MA 02142

    (857) 357-7000

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

     

    with copies to:

     

    Deborah Miller

    Chief Legal Officer

    One Broadway, 14th Floor

    Cambridge, MA 02142

    (857) 357-7000

     

    Rosemary G. Reilly, Esq.

    Wilmer Cutler Pickering Hale and Dorr LLP

    60 State Street

    Boston, Massachusetts 02109

    (617) 526-6000

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☒    Accelerated filer   ☐
    Non-accelerated filer   ☐    Smaller reporting company   ☐
         Emerging growth company   ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     


    Statement of Incorporation by Reference

    This Registration Statement on Form S-8, relating to the 2021 Stock Option and Incentive Plan (the “2021 Plan”) and the Amended and Restated 2021 Employee Stock Purchase Plan (the “2021 ESPP”) of Nuvalent, Inc. (the “Registrant”), is being filed for the purpose of registering additional securities of the same class as other securities for which a Registration Statement on Form S-8 relating to the 2021 Plan and the 2021 ESPP has previously been filed and is effective. Pursuant to General Instruction E to Form S-8, except as otherwise set forth below, this Registration Statement incorporates by reference the contents of (i) the Registration Statement on Form S-8, File No.  333-258237, relating to the 2021 Plan and the 2021 ESPP filed by the Registrant with the Securities and Exchange Commission on July 28, 2021, (ii) the Registration Statement on Form S-8, File No. 333-263926, relating to the 2021 Plan and the 2021 ESPP filed by the Registrant with the Securities and Exchange Commission on March 29, 2022, (iii) the Registration Statement on Form S-8, File No. 333-270594, relating to the 2021 Plan and the 2021 ESPP filed by the Registrant with the Securities and Exchange Commission on March 16, 2023, and (iv) the Registration Statement on Form S-8, File No.  333-277379, relating to the 2021 Plan and the 2021 ESPP filed by the Registrant with the Securities and Exchange Commission on February 27, 2024.

     

    Item 8.

    Exhibits.

    The following exhibits are incorporated herein by reference:

     

    Exhibit
    Number
      

    Description of Exhibit

       Form      File No.      Exhibit      Filing Date      Filed
    Herewith
     
    4.1    Third Amended and Restated Certificate of Incorporation of the Registrant, as amended      8-K        001-40671        3.1        6/16/2023     
    4.2    Amended and Restated Bylaws of the Registrant      10-K        001-40671        3.2        3/16/2023     
    4.3    Amended and Restated Investors’ Rights Agreement among the Registrant and certain of its stockholders, effective as of April  30, 2021      S-1        333-257730        4.3        7/7/2021     
    5.1    Opinion of Wilmer Cutler Pickering Hale and Dorr LLP                  X  
    23.1    Consent of KPMG LLP, independent registered public accounting firm                  X  
    23.2    Consent of Wilmer Cutler Pickering Hale and Dorr LLP (included in Exhibit 5.1)                  X  
    24.1    Power of Attorney (included on the signature pages of this registration statement)                  X  
    99.1    2021 Stock Option and Incentive Plan and forms of award agreements thereunder      S-1/A        333-257730        10.2        7/26/2021     
    99.2    Amended and Restated 2021 Employee Stock Purchase Plan      10-Q        001-40671        10.1        8/10/2022     
    107    Filing Fee Table                  X  


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Cambridge, Commonwealth of Massachusetts, on this 27th day of February, 2025.

     

    NUVALENT, INC.
    By:  

    /s/ James R. Porter

      Name: James R. Porter, Ph.D.
      Title: President and Chief Executive Officer

    POWER OF ATTORNEY AND SIGNATURES

    KNOW ALL BY THESE PRESENT, that each individual whose signature appears below hereby constitutes and appoints each of James R. Porter, Alexandra Balcom and Deborah Miller as such person’s true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for such person in such person’s name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement on Form S-8, and to file the same, with all exhibits thereto, and all documents in connection therewith, with the Securities and Exchange Commission granting unto each said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that any said attorney-in-fact and agent, or any substitute or substitutes of any of them, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Name

      

    Title

      

    Date

    /s/ James R. Porter

    James R. Porter, Ph.D.

      

    President and Chief Executive Officer and Director

    (Principal Executive Officer)

       February 27, 2025

    /s/ Alexandra Balcom

    Alexandra Balcom

      

    Chief Financial Officer

    (Principal Accounting Officer and Principal Financial Officer)

       February 27, 2025

    /s/ Grant Bogle

    Grant Bogle

       Director    February 27, 2025

    /s/ Emily Drabant Conley

    Emily Drabant Conley, Ph.D.

       Director    February 27, 2025

    /s/ Gary Gilliland

    Gary Gilliland, M.D., Ph.D.

       Director    February 27, 2025

    /s/ Andrew A. F. Hack

    Andrew A. F. Hack, M.D., Ph.D.

       Director    February 27, 2025

    /s/ Michael L. Meyers

    Michael L. Meyers, M.D., Ph.D.

       Director    February 27, 2025

    /s/ Joseph Pearlberg

    Joseph Pearlberg, M.D., Ph.D.

       Director    February 27, 2025

    /s/ Anna Protopapas

    Anna Protopapas

       Director    February 27, 2025

    /s/ Matthew Shair

    Matthew Shair, Ph.D.

       Director    February 27, 2025

    /s/ Sapna Srivastava

    Sapna Srivastava, Ph.D.

       Director    February 27, 2025

    /s/ Cameron A. Wheeler

    Cameron A. Wheeler, Ph.D.

       Director    February 27, 2025
    Get the next $NUVL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NUVL

    DatePrice TargetRatingAnalyst
    11/24/2025Buy
    Truist
    11/12/2025$126.00Buy
    Canaccord Genuity
    10/16/2025$115.00Buy
    Stifel
    10/15/2025$135.00Overweight
    Cantor Fitzgerald
    9/4/2025$122.00Buy
    Guggenheim
    9/3/2025$105.00Outperform
    Raymond James
    8/19/2025$112.00Overweight
    Piper Sandler
    3/14/2025$100.00Neutral → Buy
    UBS
    More analyst ratings

    $NUVL
    SEC Filings

    View All

    Nuvalent Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Nuvalent, Inc. (0001861560) (Filer)

    1/14/26 6:30:30 AM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-3ASR filed by Nuvalent Inc.

    S-3ASR - Nuvalent, Inc. (0001861560) (Filer)

    12/22/25 7:51:02 AM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nuvalent Inc. filed SEC Form 8-K: Other Events

    8-K - Nuvalent, Inc. (0001861560) (Filer)

    12/16/25 10:06:42 AM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NUVL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Nuvalent to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

    CAMBRIDGE, Mass., Feb. 5, 2026 /PRNewswire/ -- Nuvalent, Inc. (NASDAQ:NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D., Chief Executive Officer, and Alexandra Balcom, Chief Financial Officer, will participate in a fireside chat during the Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12, 2026, at 1:30 p.m. ET in NYC. A live webcast will be available in the Investors section of Nuvalent's website at www.nuvalent.com,

    2/5/26 6:30:00 AM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nuvalent Announces OnTarget 2026 Operating Plan Progress and Outlines Key Anticipated 2026 Milestones

    FDA accepted NDA for zidesamtinib for the treatment of TKI pre-treated patients with advanced ROS1-positive NSCLC; PDUFA target action date of September 18, 2026 NDA submission for neladalkib in TKI pre-treated advanced ALK-positive NSCLC population planned for the first half of 2026 Submission for potential indication expansion of zidesamtinib in TKI-naïve advanced ROS1-positive NSCLC population planned for the second half of 2026 Well capitalized with operating runway anticipated into 2029 Company to present at 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13th at 9:00 a.m. PT CAMBRIDGE, Mass., Jan. 12, 2026 /PRNewswire/ -- Nuvalent, Inc. (NASDAQ:NUVL), a clinical-stage

    1/12/26 6:30:00 AM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nuvalent to Present at the 44th Annual J.P. Morgan Healthcare Conference

    CAMBRIDGE, Mass., Dec. 22, 2025 /PRNewswire/ -- Nuvalent, Inc. (NASDAQ:NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D., Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 9:00 a.m. PT in San Francisco.  A live webcast will be available in the Investors section of the company's website at www.nuvalent.com, and archived for 30 days following the presentation. About Nuva

    12/22/25 6:30:00 AM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NUVL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Truist initiated coverage on Nuvalent

    Truist initiated coverage of Nuvalent with a rating of Buy

    11/24/25 8:30:57 AM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Canaccord Genuity initiated coverage on Nuvalent with a new price target

    Canaccord Genuity initiated coverage of Nuvalent with a rating of Buy and set a new price target of $126.00

    11/12/25 8:57:08 AM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Stifel resumed coverage on Nuvalent with a new price target

    Stifel resumed coverage of Nuvalent with a rating of Buy and set a new price target of $115.00

    10/16/25 8:51:17 AM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NUVL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Development Officer Noci Darlene exercised 5,500 shares at a strike of $27.85 and sold $561,422 worth of shares (5,500 units at $102.08) (SEC Form 4)

    4 - Nuvalent, Inc. (0001861560) (Issuer)

    2/2/26 4:30:46 PM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Legal Officer Miller Deborah Ann sold $1,652,176 worth of shares (15,000 units at $110.15) and exercised 15,000 shares at a strike of $27.85 (SEC Form 4)

    4 - Nuvalent, Inc. (0001861560) (Issuer)

    1/23/26 4:31:29 PM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Scientific Officer Pelish Henry E. was granted 17,500 shares and sold $501,753 worth of shares (5,160 units at $97.24), increasing direct ownership by 17% to 83,388 units (SEC Form 4)

    4 - Nuvalent, Inc. (0001861560) (Issuer)

    1/7/26 5:27:06 PM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NUVL
    Leadership Updates

    Live Leadership Updates

    View All

    Nuvalent Appoints Ron Squarer to Board of Directors

    CAMBRIDGE, Mass., Dec. 10, 2025 /PRNewswire/ -- Nuvalent, Inc. (NASDAQ:NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the appointment of Ron Squarer to its Board of Directors. "We welcome Ron to our Board of Directors, where his personal dedication to advancing oncology therapeutics, demonstrated success in evolving research and development organizations to fully integrated businesses, and proven global commercial acumen will strengthen and sharpen our pre-launch

    12/10/25 4:01:00 PM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nuvalent Highlights Pipeline and Business Achievements, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2025 Financial Results

    Initiated rolling NDA submission for zidesamtinib for TKI pre-treated patients with advanced ROS1-positive NSCLC, with target completion in the third quarter of 2025 Initiated ALKAZAR Phase 3 randomized, controlled trial of neladalkib for front-line ALK-positive NSCLC Topline pivotal data for neladalkib for TKI pre-treated patients with advanced ALK-positive NSCLC expected by year-end 2025 Preliminary data for neladalkib in patients with ALK-positive solid tumors beyond NSCLC to be presented at the ESMO Congress 2025 Jason Waters, MBA, promoted to Senior Vice President, Commercial CAMBRIDGE, Mass., Aug. 7, 2025 /PRNewswire/ -- Nuvalent, Inc. (NASDAQ:NUVL), a clinical-stage biopharmaceutical

    8/7/25 6:30:00 AM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nuvalent Appoints Christy Oliger to Board of Directors

    CAMBRIDGE, Mass., June 18, 2025 /PRNewswire/ -- Nuvalent, Inc. (NASDAQ:NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the appointment of Christy Oliger to its Board of Directors. "Christy's proven success in delivering new therapies to patients living with cancer strengthens our Board as we evolve from a development-stage company toward potential commercialization," said James Porter, Ph.D., Chief Executive Officer at Nuvalent. "We welcome her deep expertise and

    6/18/25 4:30:00 PM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NUVL
    Financials

    Live finance-specific insights

    View All

    Nuvalent Announces Positive Topline Pivotal Data from ALKOVE-1 Clinical Trial of Neladalkib for TKI Pre-treated Patients with Advanced ALK-positive NSCLC

    In 253 ALK TKI pre-treated patients, ORR by BICR was 31% (95% CI: 26, 37), with initial estimated durability of response of 64% and 53% at the 12-month and 18-month landmarks, respectivelyIn the subset of 63 TKI pre-treated patients who were lorlatinib-naïve, ORR by BICR was 46% (95% CI: 33, 59), with initial estimated durability of response of 80% and 60% at the 12- and 18-month landmarks, respectivelyNeladalkib demonstrated intracranial responses, ability to address key drivers of disease progression, and a generally well-tolerated safety profile with low rates of dose discontinuation (5%) and dose reduction (17%) due to TEAEs, consistent with its ALK-selective, TRK-sparing designCompany p

    11/17/25 6:30:00 AM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nuvalent Announces Timing of Topline Pivotal Data for TKI Pre-treated Patients with Advanced ALK-positive NSCLC from ALKOVE-1 Clinical Trial of Neladalkib

    Company to host webcast and conference call on November 17, 2025 at 8:00am ET CAMBRIDGE, Mass., Nov. 14, 2025 /PRNewswire/ -- Nuvalent, Inc. (NASDAQ:NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that the company will host a webcast and conference call on Monday, November 17, 2025 at 8:00 a.m. ET, to discuss topline pivotal data for neladalkib, an investigational ALK-selective inhibitor, in TKI pre-treated patients with advanced ALK-positive non-small cell lung cancer from the global ALKOVE-1 Phase 1/2 clinical trial.

    11/14/25 4:01:00 PM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nuvalent Announces Positive Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC

    Aligned with FDA on NDA submission strategy for TKI pre-treated patients with advanced ROS1-positive NSCLC and participation in Real-Time Oncology Review; the company plans to initiate a rolling NDA submission in July 2025 with target completion in the third quarter of 2025In 117 ROS1 TKI pre-treated patients, including 50% who had received ≥ 2 prior ROS1 TKIs ± chemotherapy, ORR by BICR was 44% (95% CI: 34, 53) with initial estimated durability of response of 78% at the 12-month landmark and 62% at the 18-month landmarkIn the subset of 55 patients treated with 1 prior ROS1 TKI (crizotinib or entrectinib) ± chemotherapy, ORR was 51% (95% CI: 37, 65) with initial estimated durability of respo

    6/24/25 6:30:00 AM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NUVL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Nuvalent Inc.

    SC 13G/A - Nuvalent, Inc. (0001861560) (Subject)

    11/14/24 4:50:28 PM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Nuvalent Inc.

    SC 13G/A - Nuvalent, Inc. (0001861560) (Subject)

    11/14/24 4:34:36 PM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Nuvalent Inc. (Amendment)

    SC 13G/A - Nuvalent, Inc. (0001861560) (Subject)

    5/15/24 6:39:30 PM ET
    $NUVL
    Biotechnology: Pharmaceutical Preparations
    Health Care